We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.51 | 2.06M |
TIDMEVG
RNS Number : 6621A
Evgen Pharma PLC
09 June 2016
For immediate release 9 June 2016
Evgen Pharma plc
("Evgen Pharma" or the "Company")
Grant of Options
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 8 June 2016, David Chadwick, the Company's Senior Clinical Study Manager, was granted nil cost options over 53,473 ordinary shares exercisable for a period of ten years from the date of grant under the Evgen Long Term Incentive Plan ("LTIP").
The number of nil cost options awarded has been calculated by reference to the three month weighted average through to the closing market price on 7 June 2016.
These nil cost options will be subject to the rules of the LTIP and will vest in proportion to a Total Shareholder Return ("TSR") between the date of grant and the third anniversary of grant.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000 Dr Stephen Franklin, CEO www.evgen.com Northland Capital Partners +44 (0) 20 3861 Limited 6625 Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance) John Howes, Rob Rees (Corporate Broking) +44 (0) 20 7466 Buchanan 5000 Mark Court, Sophie Cowles, Stephanie Watson
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. For further information please visit www.evgen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAKFDBABKDKAK
(END) Dow Jones Newswires
June 09, 2016 02:00 ET (06:00 GMT)
1 Year Evgen Pharma Chart |
1 Month Evgen Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions